SG Americas Securities LLC Sells 209,062 Shares of Hologic, Inc. (NASDAQ:HOLX)

SG Americas Securities LLC cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 91.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,109 shares of the medical equipment provider’s stock after selling 209,062 shares during the quarter. SG Americas Securities LLC’s holdings in Hologic were worth $1,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Massmutual Trust Co. FSB ADV grew its position in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 137 shares during the last quarter. Graypoint LLC increased its position in Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after purchasing an additional 147 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Hologic by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after purchasing an additional 165 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Hologic by 0.6% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock worth $2,425,000 after purchasing an additional 192 shares during the period. Finally, Curbstone Financial Management Corp boosted its stake in shares of Hologic by 0.9% during the 2nd quarter. Curbstone Financial Management Corp now owns 23,126 shares of the medical equipment provider’s stock valued at $1,717,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In other news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is owned by insiders.

Hologic Price Performance

Shares of HOLX opened at $80.26 on Wednesday. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67. The company has a market capitalization of $18.73 billion, a P/E ratio of 40.95, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. The firm has a 50 day moving average of $81.24 and a 200 day moving average of $77.51. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the company earned $0.93 EPS. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Leerink Partners lowered their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday. JPMorgan Chase & Co. upped their target price on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, September 17th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus target price of $87.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.